Initial treatment patterns over time for anaplastic oligodendroglial tumors

Katherine S. Panageas, Fabio M. Iwamoto, Timothy F. Cloughesy, Kenneth D. Aldape, Andreana L. Rivera, April F. Eichler, David N. Louis, Nina A. Paleologos, Barbara J. Fisher, Lynn S. Ashby, J. Gregory Cairncross, Gloria B.Roldán Urgoiti, Patrick Y. Wen, Keith L. Ligon, David Schiff, H. Ian Robins, Brandon G. Rocque, Marc C. Chamberlain, Warren P. Mason, Susan A. WeaverRichard M. Green, Francois G. Kamar, Lauren E. Abrey, Lisa M. DeAngelis, Suresh C. Jhanwar, Marc K. Rosenblum, Andrew B. Lassman

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Anaplastic oligodendroglial tumors are rare neoplasms with no standard approach to treatment. We sought to determine patterns of treatment delivered over time and identify clinical correlates of specific strategies using an international retrospective cohort of 1013 patients diagnosed from 19812007. Prior to 1990, most patients received radiotherapy (RT) alone as initial postoperative treatment. After 1990, approximately 50 of patients received both RT and chemotherapy (CT) sequentially and/or concurrently. Treatment with RT alone became significantly less common (67 in 19801984 vs 5 in 20052007, P < .0001). CT alone was more frequently administered in later years (0 in 19801984 vs 38 in 20052007; P < .0001), especially in patients with 1p19q codeleted tumors (57 of codeleted vs 4 with no deletion in 20052007; P < .0001). Temozolomide replaced the combination of procarbazine, lomustine, and vincristine (PCV) among patients who received CT alone or with RT (87 vs 2 in 20052007). In the most recent time period, patients with 1p19q codeleted tumors were significantly more likely to receive CT alone (with temozolomide), whereas RT with temozolomide was a significantly more common treatment strategy than either CT or RT alone in cases with no deletion (P < .0001). In a multivariate polytomous logistic regression model, the following were significantly associated with type of treatment delivered: date (5-year interval) of diagnosis (P < .0001), 1p19q codeletion (P < .0001), pure anaplastic oligodendroglioma histology (P < .01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy.

Original languageEnglish (US)
Pages (from-to)761-767
Number of pages7
JournalNeuro-oncology
Volume14
Issue number6
DOIs
StatePublished - Jun 2012

Keywords

  • 1p19q
  • PCV
  • oligoastrocytoma
  • oligodendroglioma
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Initial treatment patterns over time for anaplastic oligodendroglial tumors'. Together they form a unique fingerprint.

Cite this